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Abstract
The area under the ROC curve (AUC) and partial area under the ROC curve (pAUC) are summary
measures used to assess the accuracy of a biomarker in discriminating true disease status. The
standard sampling approach used in biomarker validation studies is often inefficient and costly,
especially when ascertaining the true disease status is costly and invasive. To improve efficiency
and reduce the cost of biomarker validation studies, we consider a test-result-dependent sampling
(TDS) scheme, in which subject selection for determining the disease state is dependent on the
result of a biomarker assay. We first estimate the test-result distribution using data arising from
the TDS design. With the estimated empirical test-result distribution, we propose consistent
nonparametric estimators for AUC and pAUC and establish the asymptotic properties of the
proposed estimators. Simulation studies show that the proposed estimators have good finite
sample properties and that the TDS design yields more efficient AUC and pAUC estimates than a
simple random sampling (SRS) design. A data example based on an ongoing cancer clinical trial is
provided to illustrate the TDS design and the proposed estimators. This work can find broad
applications in design and analysis of biomarker validation studies.
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1 Introduction
The area under the ROC curve (AUC) and partial area under the ROC curve (pAUC) are
two summary measures of accuracy of a diagnostic test or a biomarker [1, 2]. We use the
terms “biomarker” and “diagnostic test” in a generic sense to mean any measure that could
signal the onset of a disease or a disease condition. Let D be the true disease status with D =
1 for presence of disease and D = 0 for absence of disease. Let Y be a continuous measure
for a biomarker, where a higher value is indicative of increased severity of the disease. The
true and false positive rates at the threshold c are TPR(c) = Pr(Y ≥ c|D = 1) = Pr(YD ≥ c) and
FPR(c) = Pr(Y ≥ c|D = 0) = Pr(YD̄ ≥ c) respectively, where D and D̄ in indices denote the
sets {D = 1} and {D = 0}. An ROC curve is a plot of the entire set of possible true and false
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positive rates ROC(c) = {(FPR(c), TPR(c)), c ∈ (−∞, ∞)}. The AUC is defined over the
entire ROC curve as . The larger the AUC value, the more
accurate the diagnostic test is. However, in medical research, we often know a priori that a
particular test would be useful only if its false-positive rate is in a restricted range of rates.
Partial AUC (pAUC) is defined over the restricted range of false positive rates (t0, t1) with
, where q0 = FPR−1(t1) and q1 = FPR−1 (t0).
Validation of the predictive value of a biomarker or a diagnostic test usually involves large
prospective studies, in which subjects are sampled randomly from a target population.
Observing the true disease status can be costly, invasive, or time consuming and the
positivity rates for many markers can be low in the target population. Moreover, medical
investigators are often interested in the performance of a diagnostic test in a narrow range of
test results that corresponds to low false positive rates. For example, in cancer screening,
where false positivity is associated with greater risk than benefit from aggressive
intervention, partial AUC over the restricted false positive rates is of more interest [3, 4]. All
of these factors make the conventional design, in which the true disease status is ascertained
for a large number of randomly sampled subjects regardless of their test results, is inefficient
and costly. In this article, we consider test-result-dependent sampling (TDS) as an
alternative to simple random sampling (SRS) for biomarker validation. Rather than sampling
all subjects randomly from the target population, TDS allows a subset of subjects to be
sampled using a test-result-dependent sampling scheme. Depending on the specific
questions, the investigators can select more subjects from those in the range of test results
that contain the most information for statistical estimation at the design phase of the study.
By oversampling subjects with the chosen ranges of test results and undersampling subjects
outside of these ranges, the TDS design has potential to considerably improve efficiency of
estimating AUC (or pAUC) for a given number of subjects that require their true disease
status determined.
In this article, we consider test-result-dependent sampling (TDS) that consists of two
sampling components, a simple random component of subjects from the targeted study
population and a test-result-dependent component from the same population. As in the case
of verification bias in diagnostic medicine [1, 2], the TDS design will introduce bias when
standard methods are used to estimate AUC and pAUC based on TDS data. However, the
existing methods of AUC and pAUC for verification bias are not applicable to the TDS data.
Verification bias occurs primarily in population-based studies, in which a diagnostic test is
applied to all N subjects in the cohort, yielding a test result Y for all study units. As only a
subset of patients is selected to observe (verify) true disease status D, unselected patients in
the cohort are missing D. When D is missing at random (MAR) [5], the selection probability
of observing D is directly estimable. The bias in estimating AUC can be corrected by the
inverse probability weighting method for binary, ordinal or continuous diagnostic tests (e.g.
[6, 7, 8, 9, 10, 11]). In the TDS design, patients are selected to observe D depending on their
ranges of test result Y, but the size of the parent cohort from which the patients are accrued
and the test results of unscreened patients are unknown to the investigators. Indeed, such
situations occur in most cancer biomarker validation studies, in which subjects come from
hospital-based settings and randomized clinical trials and population-based study designs are
not feasible. In the TDS design, for all the subjects in the selected sample, the data available
for analysis are observed, both Y and D. Since there are no missing variables, the TDS
design is different from the verification bias problem and the inverse probability weighting
(IPW) approach for missing data is not directly applicable.
For data with a TDS design structure, standard methods of estimating AUC and pAUC yield
biased results. In this article, an empirical likelihood method is used to estimate the
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distribution of the test result Y conditional on disease status D. Unbiased estimators for
AUC and pAUC are then obtained by reweighing the standard estimators with the estimated
empirical distribution. The estimators are nonparametric in that no parametric model is
assumed for the relationship between the test result and the true disease status. Our method
is related to the general approach of outcome-dependent sampling. Weaver and Zhou [12]
and Zhou et al. [13] discussed the utility of outcome-dependent sampling schemes in
estimating the coefficients of regression models for epidemiologic studies. Zhou et al. [14]
and Wang and Zhou [15] studied empirical likelihood-based estimators for regression
models where the sample depends on the outcome or an auxiliary variable. Outcome-
dependent sampling is also used in econometrics. Cosslett [16, 17] proposed a constrained
likelihood estimator for regression coefficients of a categorical regression model.
Morgenthaler and Vardi [18] studied a weighted likelihood method for data arising from
length-bias sampling.
For AUC and pAUC estimation, nonparametric methods are generally preferable to their
parametric counterparts since they require fewer assumptions. Bamber [19] showed that
AUC is the probability that a randomly observed test result in diseased subjects is higher
than a randomly observed test result in non-diseased subjects, i.e. Pr(YD > YD̄). Hanley and
McNeil [20] showed that the AUC estimator based on the trapezoidal rule is equivalent to
the Mann-Whitney U statistic. DeLong et al. [21] and Wieand et al. [22] studied
nonparametric estimation of AUC and testing of AUC differences for paired biomarkers.
Partial AUC (pAUC) can be considered an average of TPR(c) across all FPR(c) where
FPR(c) ∈ (t0, t1). Thompson and Zucchini [23], McClish [24] and Jiang et al. [25] studied
parametric pAUC estimation assuming bivariate normal models. Zhang et al. [26], Dodd and
Pepe [4], and He and Escobar [27] studied nonparametric pAUC estimation by extending the
approach of DeLong et al. [21]. In all these papers, the data are assumed to be a simple
random sample of the targeted patient population.
The rest of the paper is organized as follows. In Section 2, we specify the likelihood for data
arising from a TDS design and propose a nonparametric empirical likelihood method to
estimate the distribution of the test result conditional on the disease status. Section 3
presents the nonparametric AUC estimator under the TDS design and establishes its
asymptotic properties. Section 4 studies the nonparametric pAUC estimator under the TDS
design. Section 5 describes the finite sample properties of the proposed estimators under the
TDS design. The efficiency gain of the proposed estimators under the TDS design relative to
the standard estimators under the SRS design is also investigated. We illustrate in Section 6
the proposed method with an example. The article concludes with some remarks in Section
7. Proofs of the asymptotic properties for the proposed estimators are sketched in the
Appendix.
2 Estimation of Test Result Distribution
We consider test-result-dependent sampling (TDS) which consists of a simple random
component and a test-result-dependent component. Assume that the test result Y falls into
one of K mutually exclusive intervals Ck = (ak−1, ak), k = 1, …, K where ak−1 < ak and a0 =
−∞, aK = ∞. One observes a test-result-dependent component {Yki, Dki}, i = 1, …, nk
conditional on whether Y belongs to stratum Ck as well as a simple random component
{Y0i, D0i}, where i = 1, …, n0. The combined sample size of the two components is
.
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Denote by f(Y, D) the joint density function of Y and D. Let psi = f (Ysi, Dsi), s = 0, …, K, i
= 1, …, ns, and θk = Pr(Y ∈ Ck), k = 1, …, (K − 1), θ = (θ1, …, θK−1)T and .
The empirical likelihood of {Ysi, Dsi} under the TDS design is then
Based on empirical likelihood theory [28, 29, 30], one can maximize the log(L(θ, psi)) under
the following constraints below to find estimates of θ and psi:
where I(·) is the indicator function. Using Lagrange multipliers, one can show that the
maximum of log(L(θ, psi)) is attained at
(1)
where  and θ̂k can be obtained by solving ∂lp(θ)/∂θ = 0, where
(2)
Following Qin and Lawless [30], we can show θ̂ asymptotically follows a normal
distribution. That is, under general regularity conditions, if ns/n → ρs as n → ∞ where 0 <
ρs < 1, s = 0, …, K − 1, we have , where 
with ξsi is given in the Appendix.
3 Nonparametric Estimation of AUC
The AUC is defined as . Under simple random sampling, the
nonparametric AUC estimator [19, 20] is
(3)
where Iij = I(Yi > Yj), i, j = 1, …, n, and ÂSRS is known to have good properties under
simple random sampling. However, ÂSRS yields biased estimates under the TDS design. To
obtain unbiased AUC estimates for the TDS design, we reweight the standard AUC
estimator with the estimates p̂si in (1) and propose the following nonparametric estimator
under the TDS design:
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For notational simplicity, we have replaced the double subscripts si in p̂si with a single
subscript i with i = 1, · · ·, n in p̂i. Let  and
(5)
Assuming the U-process Un(A, θ) = n1/2 {Rn(A, θ) − E[Rn(A, θ)]} is equicontinuous, we
are able to show that the proposed estimator ÂTDS for AUC converges asymptotically to a
normal distribution, that is,
(6)
where Λn is given in the Appendix.
4 Nonparametric Estimation of pAUC
Denote the partial AUC restricted in (t0, t1) by At. Let q0 = FPR−1(t1) and q1 = FPR−1(t0).
By the definition of partial AUC, we have
Under simple random sampling, Dodd and Pepe (2003) proposed a nonparametric estimator
for partial AUC: , or equivalently,
(7)
and they illustrated that  is consistent and more robust than other estimators that make
parametric assumptions. We propose the following nonparametric pAUC estimator for the
TDS design:
(8)
where  and . To
estimate  in formula (8), we first estimate , then limit  to the range (t0, t1).
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Besides , we may also consider a standardization recommended by McClish [24] and
Jiang et al. [25]. Let τt = At/(t1 − t0) = Pr(YD > YD̄| FPR ∈ (t0, t1)). The τt may be
interpreted as the average true positive rate over the range of false positive rates of concern.
The estimator τ̂t is given by
We establish the asymptotic properties of  by letting
 and FP ̃Rj = Σip̃i(1 − Di)I(Yi >
Yj)/Σip̃i(1 − Di) where p̃i is given in (5). Let , and 
be the number of elements of Δ falling into the sth stratum of the test result Y. Assuming the
U-process  is equicontinuous and  as n →
∞, we can show that the proposed estimator  for τt follows asymptotically a normal
distribution, that is, , where Ωn is given in the Appendix.




Simulation studies were conducted to evaluate the performance of the AUC estimator ÂTDS
and the pAUC estimator  under the TDS design. First, we illustrate the unbiasedness of
the estimators under the TDS design. Second, we assess the performance of the proposed
variance estimators under different specifications of subject allocations and cutoff points for
stratification. The structure of the TDS design is determined by several factors, including
number of strata K, choice of cutoff points (a1, a2, · · ·, aK−1) and subject allocations among
strata ns = (n0, n1, · · ·, nK). Last, we examine the efficiency gain of the use of the TDS
design and the proposed estimators over the SRS design and the standard estimators.
In all simulations, we assume D ~ Bernoulli(0.3),  and . To
generate the TDS data, we first generate a random sample of size n0, and then generate the
test-result-dependent (TDS) component. The TDS component consists of samples of sizes
n1, n2, n3 from the lower tail, the middle region and the upper tail of Y, respectively. These
regions are defined by the cutoff points (a1, a2). For the purpose of illustration, we use K = 3
and (a1, a2) = (μY − α × σY, μY +α × σY ) for AUC, and (a1, a2) = (q0, q1) for partial AUC,
where (q0, q1) are the quantiles of YD̄ at the pre-specified (t0, t1). All simulation studies are
based on 5, 000 independent runs.
5.1 Unbiasedness of Proposed Estimators Under TDS
To illustrate the unbiasedness of the proposed estimator ÂTDS under the TDS design, we
generated TDS data with K = 3, (a1, a2) = (μY − ασY, μY + ασY ) and ns = (n0, n1, n2, n3) =
(180, 60, 60, 60), where α = 1 or 1.5, μY and σY are mean and standard deviation of Y.
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Table 1 lists the mean (Estimate) and the relative bias (Bias%) of ÂSRS (3) and ÂTDS (4)
under the TDS design. The standard AUC estimator ÂSRS yields significant bias under the
TDS design, and the bias becomes larger as the cutoff points move away from the center of
the test-result distribution. In a contrast, for the same TDS data, the proposed estimator
ÂTDS yields unbiased estimates. In the illustration of the unbiasedness of the proposed
pAUC estimator , we chose the combinations: (t0, t1) = (0, 0.1), ns = (180, 90, 90), and
(t0, t1) = (0.1, 0.2), ns = (180, 60, 60, 60). Notice that two methods were used to determine
the cutoff points for stratification: either the true quantiles (q0, q1) of YD̄ or the quantiles
(q̂0, q̂1) of the empirical distribution ŶD̄ at (t0, t1). The standard estimator  (7) and the
proposed estimator  (8) were applied to the same TDS data. As seen in Table 2, 
yields extreme bias under the TDS design, while the proposed estimator for the TDS design
 performs well with essentially no bias.
5.2 Performance of Variance Estimators under TDS
We examine the finite sample performance of the proposed variance estimators for ÂTDS
and  by simulating the TDS data with different structures. Table 3 and Table 4 lists the
mean of estimates (Estimate), the relative bias (Bias%), the simulated standard error (SE),
the mean of the estimated standard errors ( ) and the coverage percentage of the 95%
confidence interval (CP). Estimated standard errors were obtained by the proposed variance
estimators, in which large sample quantities were replaced with finite sample quantities. As
seen in Table 3, the proposed estimator ÂTDS has good finite sample property under TDS
data with several specifications of subject allocation and cutoff points. The estimated
standard errors in all cases are very close to their true values and the empirical 95%
coverage percentage are close to the nominal value. Different structures of the TDS design
result in slightly different true standard errors, but the proposed estimators and their variance
estimators perform fairly well in all these cases. Similar results are observed in Table 4 for
the proposed estimator  for partial AUC under various TDS designs. Simulation studies
were conducted under many combinations on subject allocation and cutoff points, but we
have not seen a systematic pattern that a specific combination consistently yields most
efficiency gain.
5.3 Efficiency Comparison of TDS Design over SRS Design
One of the main reasons to use the TDS design over the standard SRS design in biomarker
validation is that the TDS design improves efficiency in assessing the performance of a
diagnostic test or biomarker with the same number of subjects. The strategy could be
particularly useful for the estimation of the partial area under ROC curve (pAUC). In this
case, oversampling can be done by concentrating those subjects with test results largely
corresponding to the range of false-positive rates of interest. To illustrate this, we generated
separate data for the SRS design and the TDS design of the same sample size n = 360.
Efficiency comparison is made by applying  to the TDS data while applying  to the
SRS data. If simulation shows that the TDS design yields better efficiency over the SRS
design in estimating pAUC, it would support the utility of the TDS design over the SRS
design in biomarker validation. Table 5 lists Estimate, Bias% and simulated standard error
(SE), ratio of mean square error (RMSE). subject proportion (nratio%) for the TDS data and
the SRS data, where ns = (180, 90, 90) is taken for (t0, t1) = (0, 0.1). Table 5 shows
considerable efficiency gain using the TDS design to estimate partial AUC under various
scenarios, regardless of whether the true quantile (q0, q1) or (q̂0, q̂1) was used as cutoff
points for stratification. The results indicate that a combined use of the TDS design and the
proposed pAUC estimator can lead to more than 50% efficiency gain over that from the SRS
design and the standard pAUC estimator. Based on similar simulations, the efficiency gain
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for estimating AUC under the TDS design is relatively small. This is understandable since
the TDS design oversamples patients corresponding to the range of interest. Thus, the
efficiency gain of the TDS design is not as high in estimating AUC, since it is an average
across the full range of test results, thereby counteracting the effect of the TDS design by
oversampling the two tails and undersampling in between.
6 Data Example
We have focused on the TDS design and emphasized its potential to improve efficiency over
the SRS design in AUC and partial AUC estimation. In practice, biomarker data with the
TDS structure may also come from existing studies, in which subjects are not a simple
random sample from the target population and analyzing the available data ignoring this fact
will lead to biased results. In this section, we use a randomized clinical trial to illustrate this
idea and show how the proposed TDS methods can be applied. CALGB 30801 is an ongoing
phase III lung cancer trial conducted at the Cancer and Leukemia Group B (CALGB) [31].
A total of 216 patients with positive COX-2 expression are to be randomized with equal
allocation to a standard chemotherapy (arm A) or celecoxib combined with standard
chemotherapy (arm B). The primary objective of the trial is to evaluate the survival benefit
of celecoxib (a COX-2 inhibitor) among patients with positive COX-2 expression. COX-2 is
a protein over-expressed in lung cancers and its intensity is measured on a continuous scale
ranging from 0 to 10. Based on preliminary data [32], the proportions of patients with
negative (COX-2 < 2), moderate (2 ≤ COX-2 < 4) and positive (COX-2 ≥ 4) expression are
about 60%, 13% and 27% respectively in the target population. Therefore, approximately
800 patients are to be screened to accrue the 216 positive patients. As a secondary objective,
the investigators are interested in validating the prognostic value of COX-2 for survival in
those patients who receive the standard chemotherapy. To answer this question, data from
patients who have a full range of COX-2 scores (negative, moderate, positive) and are
treated by standard chemotherapy are needed. To avoid the costly option of treating and
following the large number of COX-2 negative patients, the investigators decided to select
about 1/4 of all negatives to treat and follow for long term survival. At the end of the trial,
the data available for assessing the prognostic value of COX-2 has a data structure of the
TDS design. The simple random component (SRC) include all negatives when 1/4 of the
positives are enrolled, all moderates when 1/4 of the positives are enrolled, and the first 54
positives on arm A. The expected sizes of the three SRC strata are n0,1 = 120, n0,2 = 26, n0,3
= 54, respectively. The rest of patients receiving standard chemotherapy, including n1 = 0
negatives, n2 = 78 moderates and n3 = 54 positives patients, makes up of the test-result-
dependent component (TDC) of the TDS design. For this purpose of illustration, we define
D = 1 for patients surviving less than 6 years and D = 0 otherwise. Since very few patients
are expected to drop out before 6 years of follow-up in this trial, we ignore the issue of
censoring for those patients who are followed less than 6 years. However, when censoring is
non-ignorable and the predictive accuracy of the biomarker over time is of interest, an
estimator that takes into account both time-to-event endpoint and censoring is warranted.
This is a research topic for the future.
The CALGB trial is still open for patient accrual and the final data are not yet available for
analysis. To illustrate the proposed AUC and pAUC estimators, we resampled a cohort of
800 patients with full range of COX-2 measures using the data from a preliminary COX-2
study [32], and used the cohort to create a dataset with the same data structure of the TDS
design as CALGB 30801. The specific goal is to evaluate how well COX-2 expression
levels predict death within 6 years) among the patients who receive only standard
chemotherapy. Figure 1 shows the estimated ROC curves by the standard method ignoring
the TDS data structure (Left) and the proposed method (Right), and the shaded areas
indicate the estimated pAUCs. For AUC, the vector of cutoff points is set to (−∞, 3, 4, ∞).
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For pAUC, the range of t is set to (0, 0.1), which approximately corresponds to cutoff points
(−∞, 4, ∞), such that n1 = 0 and n2 = 54 in the notation for pAUC in Section 5. The
estimated AUC using ÂTDS is 0.8052 with a 95% confidence interval [0.7445, 0.8544]. The
biased estimator ÂSRS yields an AUC estimate of 0.7749 with a 95% confidence interval
[0.7192, 0.8223]. When ÂSRS is applied only to the SRS component of the dataset, the
estimated AUC is 0.8125 with a 95% confidence interval [0.7400, 0.8685]. Assuming that
the investigators are interested in the performance of the biomarker within a low FPR range t
∈ (0, 0.1), the estimated pAUC using  is 0.0216 with a 95% confidence interval
[0.0159, 0.0291]. The biased estimator  yields a pAUC estimate of 0.0151. The
estimated pAUC is 0.0115 when  is applied only to the SRS component of the dataset.
7 Discussion
We propose nonparametric estimators for the area under the ROC curve (AUC) and the
partial area under the ROC curve (pAUC) for data arising from a test-result-dependent
sampling scheme (TDS). We demonstrate that the estimated empirical distribution of test
results can be used to reweight the standard estimators of AUC and pAUC to provide valid
inference for data arising from the TDS design. We establish the asymptotic properties of
the proposed estimators under general regularity conditions. We also demonstrate good
finite sample properties for the proposed estimators and their variance estimators under
various specifications of the extent of separation of diseased vs. non-diseased subjects,
cutoff points for stratification and subject allocation among strata. The proposed estimators
are nonparametric in the same sense as the nonparametric AUC and pAUC estimators under
the SRS design [4, 20]; and these estimators make no parametric assumptions about the
relationship between test results and true disease status.
The test-result-dependent (TDS) design is motivated by the need for better efficiency for
biomarker validation studies with limited resources. It is particularly useful when
determining the true disease status is expensive, invasive or time consuming. In this article,
the data arising from the TDS design consists of two components: a simple random
component and a test-result-dependent component. The determination of the true disease
status of a subject in the TDS component is dependent on the test results. More specifically,
the selection of the TDS component is dependent on the intervals defined by pre-chosen
cutoff points for stratification on the test result.
Simulations confirm that the proposed estimators for AUC and partial AUC effectively
correct the bias introduced by the TDS design. Simulations also show that efficiency gains
can be achieved by adopting a TDS design over a SRS design, particularly when the
estimation of partial AUC is of interest. It is not surprising to see that much better precision
is achieved by the TDS design for partial AUC estimation since more subjects fall into the
false-positive range of interest as compared to the SRS design. In addition, greater efficiency
gain occurs for pAUC estimation when (q0, q1) is unknown and has to be estimated than
when (q0, q1) is known. The efficiency gain in estimating AUC under a TDS design is also
understandable since a SRS design leads to an uneven distribution of subjects in different
segments of the test results and hence leads to lower precision in AUC estimation.
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Appendix
Let , s = 0, · · ·, K, i = 1, · · ·, ns, k = 1, · · ·,
K − 1, where .
Let
and
where PK−1 is the (K − 1)th-order matrix with all elements 1.
Proof for Asymptotic Distribution of θ̂
The proof follows Owen [28, 29] and Qin and Lawless [30]. Since ns/n, s = 0, · · ·, K − 1
converge to ρs as n → ∞, nK/n converges to . Using the Taylor expansion of
lp(θ̂) (see (2)) at the true value θ and noticing , we have
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where . Rewriting the sum  as
, we can apply the central limit theorem to each term,
and it is easy to show  converges as n tends to infinity. Thus we have
n1/2(θ̂− θ) converges to normal distribution as n tends to infinity. Let ,
we have
Proof for Asymptotic Distribution of ÂTDS
It is obvious that Rn(ÂTDS, θ̂) = 0. Denote e(A, θ) = E(Rn(A, θ)). Expanding Rn(ÂTDS, θ̂) at
(A, θ), it follows from the condition that Un(A, θ) is equicontinuous that
where  and
Rewrite ξsi in the proof of asymptotic distribution for θ̂ using single subscript as ξi. We
have
where  where Rij = p̃ip̃jDi(1 − Dj)(Iij − A). The last identity
follows by the asymptotic property of θ̂ and by the limit distribution theorem of U-Statistic
[33].
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Rewrite  using double subscripts as
, then we can apply the central limit theorem to
each term , s = 0, · · ·, K. Let , it
follows that  as n → ∞.
Proof of Asymptotic Distribution for τ̂t
Denote . Expanding  at the true value (τt, θ), it follows from
the condition that  is equicontinuous that
where  and
By the proof of asymptotic distribution for t ̂heta, we have
where , and the second identity follows by the
limit distribution theorem of U-statistic, similarly to the proof of Theorem 1. Rewrite
 using double subscripts as . Similarly, rewrite
 as . Applying the central limit theorem to
 and  respectively. Let , we have
.
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Figure 1. COX-2 ROC Curve Estimated by Standard Method and Proposed Method
Note: The left ROC curve is estimated by the standard method for a SRS design; the right
ROC curve is estimated by the proposed method for a TDS design. The shaded areas denote
the partial area under curve (pAUC) with t ∈ (0, 0.1)
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